2017-08-17T09:32:36-05:00 2016-12-31 BOND BEEBE PC 4600 EAST WEST HWY 900 BETHESDA MD 208143423 990 2016-01-01 042531031 NATIONAL FOUNDATION FOR CANCER RESEARCH % SUJUAN BA NATI 3016541250 4600 EAST-WEST HIGHWAY Suite 525 BETHESDA MD 20814 FRANKLIN C SALISBURY JR CEO 3016541250 2017-08-17 true RICHARD L RUVELSON P00234075 3012726000 2017-08-16 66.195.210.98 52746520172295000000 2017-08-17 P 483B3F99E9CD71719F6CCAA667530D61A598C20D EFE937D907E9188D51497D9C700ABA7D032A681F 2016 2021-01-29 14:40:06Z FRANKLIN C SALISBURY JR 4600 EAST-WEST HWY SUITE 525 BETHESDA MD 20814 19960703 false 5582 X WWW.NFCR.ORG X 1973 MA TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER. 7 7 31 100 9182 5446 13729474 13952247 0 0 291958 364941 280368 346806 14301800 14663994 2494883 3164316 0 0 2283506 2340557 45138 45692 2385337 8331748 7615468 13155275 13166033 1146525 1497961 13163238 15027884 2236940 2474411 10926298 12553473 X THE NATIONAL FOUNDATION FOR CANCER RESEARCH (NFCR) IS A LEADING PUBLIC CHARITY DEDICATED TO FUNDING CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO CANCER PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND, ULTIMATELY, CURES FOR CANCER. NFCR PROMOTES AND FACILITATES COLLABORATION AMONG SCIENTISTS TO ACCELERATE THE PACE OF DISCOVERY FROM BENCH TO BEDSIDE. SINCE 1973, NFCR HAS PROVIDED MORE THAN $350 MILLION IN SUPPORT OF DISCOVERY-ORIENTED CANCER RESEARCH FOCUSED ON UNDERSTANDING HOW AND WHY CELLS BECOME CANCEROUS, AND ON PUBLIC EDUCATION RELATING TO CANCER PREVENTION, DETECTION, AND TREATMENT. NFCR SCIENTISTS ARE DISCOVERING CANCER'S MOLECULAR MYSTERIES AND TRANSLATING THEIR DISCOVERIES INTO THERAPIES THAT HOLD THE HOPE FOR CURING CANCER. NFCR IS ABOUT SAVING LIVES NFCR-FUNDED RESEARCHERS ARE MAKING PROGRESS EVERY DAY IN THEIR PURSUIT OF CANCER CURES, AND THIS IS ONLY POSSIBLE WITH THE FINANCIAL SUPPORT OF MILLIONS OF DONORS NATIONWIDE. ONE STEP AT A TIME, WE ARE GETTING CLOSER TO O false false 4594927 3104316 CANCER RESEARCH - SEE SCHEDULE O 5214010 CANCER PREVENTION EDUCATION TO THE PUBLIC - SEE SCHEDULE O 9808937 true true false false false true false false false true true false false true false true false true false false true true true true true false false true true true false false false false false false false false true false false false false true false false false true 35 0 true 31 true true true true HK false false false true true false false false false false false false X 7 7 true false false false false false false true true false true true true true true true true true true true false AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X SUJUAN BA 3016541250 4600 EAST-WEST HIGHWAY SUITE 525 BETHESDA MD 20814 X JOSEPH F FRANLIN CHAIR 5.0 0.0 X X 0 0 0 WENDY P DENNARD TREASURER (EFF. 6/2016) 2.0 0.0 X X 0 0 0 MARK R BARAN DIRECTOR (TREAS. THRU 6/2016) 2.0 0.0 X X 0 0 0 JUDITH P BARNHARD DIRECTOR 2.0 0.0 X 0 0 0 MICHAEL BURKE DIRECTOR 2.0 0.0 X 0 0 0 PADMAKUMAR KAIMAL DIRECTOR 2.0 0.0 X 0 0 0 EDWARD S WEST DIRECTOR 2.0 0.0 X 0 0 0 FRANKLIN C SALISBURY JR CHIEF EXECUTIVE OFFICER 40.0 2.0 X 312185 0 69271 SUJUAN BA PRESIDENT/COO 40.0 2.0 X 310693 0 66406 KWOK LEUNG CFO/SECRETARY 40.0 5.0 X 146126 0 25403 YI WANG CHIEF STRATEGY OFFICER 40.0 0.0 X 191829 0 31677 960833 0 192757 4 false true false REDFIELD DIRECT LLC 1901 HOWARD STREET OMAHA NE 68102 LABEL PRINTING 861942 CALMARK GROUP LLC 6755 S SAYRE AVE BEDFORD PARK IL 60638 MAILSHOP 762007 CP DIRECT INC 4600 A BOSTON WAY LANHAM MD 20706 PRINTING 597928 MACKAY MITCHELL ENVELOPE CO 2100 ELM ST SE MINNEAPOLIS MN 55414 ENVELOPE PRINTING 405121 KEY ACQUISITION PARTNERS 2525 RIVA ROAD STE 145 ANNAPOLIS MD 21401 LIST BROKER 336964 8 X 80043 369952 13502252 712105 13952247 0 283243 283243 0 4256 4256 0 0 0 5331893 5250195 81698 81698 81698 31278 369952 46514 -15236 -15236 0 0 0 0 0 0 MAILING LIST RENTALS 541800 357786 9182 348604 357786 14663994 9182 702565 X 2386287 2386287 212529 212529 565500 565500 0 930084 753338 154055 22691 0 1103310 728636 182135 192539 105600 63978 18341 23281 78285 50935 15740 11610 123278 89065 20327 13886 0 96272 26676 69596 41680 41680 0 45692 45692 59747 59747 435308 278074 131257 25977 3432 3432 250339 43226 199048 8065 432264 316229 1803 114232 0 195158 140834 32455 21869 77512 55220 22234 58 0 43687 43687 0 0 15391 11089 2565 1737 36618 26379 6110 4129 DIRECT MAIL PROGRAMS 5707125 3872848 1834277 LOCK BOX SERVICE 139280 98853 40427 PROCESS FEES-LIST SALES 64126 45554 18572 PLANNED GIVING 10739 10739 6790 495 6295 13166033 9808937 971759 2385337 X 6190844 4447598 0 1743246 1000 1000 2823984 4121992 0 0 289287 137805 0 0 0 0 0 0 0 0 389623 367657 234488 187014 54121 47474 7228623 7953047 442 442 0 0 0 0 2376158 2398467 13163238 15027884 2213578 2455944 0 0 23362 18467 0 0 0 0 0 0 0 0 0 0 0 0 2236940 2474411 X 7548830 9030911 1418289 1539542 1959179 1983020 10926298 12553473 13163238 15027884 1497961 129214 X false true X true false X 13288283 12996075 14884024 13729474 13952247 68850103 0 0 13288283 12996075 14884024 13729474 13952247 68850103 574544 68275559 451210 302464 334775 372780 287499 1748728 6883 7420 16841 9182 40326 695622 320737 363577 341191 348604 2069731 72708888 0.93903 0.94044 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 100 2990 true true 7627682 3687809 22308 3173483 8164316 7771063 3491261 -158768 3475874 7627682 7621530 3324595 142232 3317294 7771063 7363227 2824789 170917 2737403 7621530 6372438 3373522 194219 2576952 7363227 0.56850 0.24290 0.18860 false false 2464 1848 616 232024 185166 46858 47474 AMOUNT HELD IN TRUST BY OTHERS 2398467 2398467 0 0 X 14825713 129214 32500 5 161719 14663994 14663994 13321189 32500 122656 155156 13166033 13166033 PART V, LINE 4 - INTENDED USE OF ENDOWMENT FUNDS: THE PRINCIPAL ACTIVITIES OF NFCR ARE RAISING FUNDS AND FIGHTING CANCER THROUGH RESEARCH IN PREVENTION, EARLIER DIAGNOSTIC TECHNIQUES, MORE EFFECTIVE TREATMENTS AND ULTIMATELY, ACHIEVING ONE OF MEDICINES GREATEST GOALS: CURING CANCER TO SAVE LIVES. THE FOUNDATION FULFILLS THIS MISSION BY FUNDING ACROSS THE WORLD OUTSTANDING SCIENTISTS THAT PIONEER CANCER RESEARCH AND FUNDING CANCER PREVENTION EDUCATION PROGRAMS. THE DESIGNATED NET ASSETS, TEMPORARILY RESTRICTED NET ASSETS, AND PERMANENTLY RESTRICTED NET ASSETS ALL ARE INTENDED TO PROVIDE FUNDING FOR SUCH RESEARCH AND EDUCATION PROGRAMS. PART X, LINE 2 - FIN 48 FOOTNOTE: Accounting principles generally accepted in the United States of America require management to evaluate income tax positions taken and accrue an income tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service. Management has evaluated the income tax positions taken and concluded that as of December 31, 2016 there are no uncertain positions taken or expected to be taken that would require accrual of a liability in the consolidated financial statements. NFCR and affiliates are subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress for any tax periods. PART XI, LINE 2D - OTHER REVENUES INCLUDED ON FINANCIALS, NOT FORM 990: $5 - RELATED ORGANIZATIONS' REVENUES PART XII, LINE 2D - OTHER EXPENSES INCLUDED ON FINANCIALS, NOT FORM 990: $122,656 - RELATED ORGANIZATIONS' EXPENSES true Europe (Including Iceland and Greenland) CANCER 50000 CHECK 30000 SEE PART V FMV East Asia and the Pacific CANCER 50000 CHECK 425500 SEE PART V FMV 2 RESEARCH REVIEW Europe (Including Iceland and Greenland) 1 5000 CHECK RESEARCH REVIEW East Asia and the Pacific 1 5000 CHECK false false false false false false PART I, LINE 2 - PROCEDURES FOR MONITORING USE OF GRANTS OUTSIDE USA: GRANT AND CONTRACT RECIPIENTS ARE REQUIRED TO SUBMIT QUARTERLY EXPENDITURE REPORTS AND ANNUAL PROGRESS REPORTS TO NFCR. PART II, LINE 1(1), COLUMN H - DESCRIPTION OF NON-CASH ASSISTANCE: PROVIDED MATERIALS, CHEMICALS AND EQUIPMENT. PART II, LINE 1(2), COLUMN H - DESCRIPTION OF NON-CASH ASSISTANCE: PROVIDED MATERIALS, CHEMICALS, AND EQUIPMENT. X X X X X X true MERKLE INC DIRECT MAIL COUNSEL false 7049527 45692 7003835 7049527 45692 7003835 AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WY DAFFODILS 94315 63037 31278 14780 1636 8083 PARTY FOR LIFE 16112 16112 344 101 290803 290803 21671 401230 369952 31278 14780 1636 30098 46514 -15236 true THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE 445 NORTH FIFTH ST SUITE 600 PHOENIX AZ 85004 753065445 501(c)(3) 190824 RESEARCH CONTRACTS ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 472209056 501(c)(3) 92958 46528 FMV CHEMICALS & EQUIP RESEARCH CONTRACTS BETH ISRAEL HOSPITAL 330 BROOKLINE AVE BOSTON MA 02215 042103881 501(c)(3) 79458 RESEARCH CONTRACTS CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE CLEVELAND OH 44106 341018992 501(c)(3) 62468 RESEARCH CONTRACTS DANA-FARBER CANCER INSTITUTE 44 BINNEY ST MAIL STOP L229 BOSTON MA 02115 042263040 501(c)(3) 53400 RESEARCH CONTRACTS MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 02241 041564655 501(c)(3) 279095 4987 FMV CHEMICALS & EQUIP RESEARCH CONTRACTS THE SCRIPPS RESEARCH INSTITUTE 10550 N TORREY PINES RD LA JOLLA CA 92037 330435954 501(c)(3) 300000 RESEARCH CONTRACTS UNIVERSITY OF TEXAS - MD ANDERSON CANCER CENTER PO BOX 4390 HOUSTON TX 77210 746001118 501(c)(3) 50000 55000 fmv chemicals & equip RESEARCH CONTRACTS UNIVERSITY OF MARYLAND 220 ARCH ST OFFICE LEVEL 2 BALTIMORE MD 21201 526002033 501(c)(3) 63416 50000 fmv chemicals & equip RESEARCH CONTRACTS VIRGINA COMMONWEALTH UNIVERSITY PO BOX 980568 RICHMOND VA 23298 546001758 501(C)(3) 50000 RESEARCH CONTRACTS YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 06508 060646973 501(c)(3) 74945 RESEARCH CONTRACTS KUMC RESEARCH INSTITUTE INC 3901 RAINBOW BLVD MAIL STOP 1039 KANSAS CITY KS 66103 481108830 501(c)(3) 9998 RESEARCH CONTRACTS MAYO CLINIC PO BOX 860334 MINNEAPOLIS MN 55468 416011702 501(C)(3) 79584 RESEARCH CONTRACTS UNIVERSITY OF PENNSYLVANIA 3451 WALNUT ST PHILADELPHIA PA 19104 231352685 501(C)(3) 12500 RESEARCH CONTRACTS 14 ALBERT SZENT-GYORGYI PRIZE 1 25000 CANCER RESEARCH 4 127529 RESEARCH REVIEW 3 60000 PART I, LINE 2 - PROCEDURES FOR MONITORING USE OF GRANT FUNDS IN USA: GRANT AND CONTRACT RECIPIENTS ARE REQUIRED TO SUBMIT QUARTERLY EXPENDITURE REPORTS AND ANNUAL PROGRESS REPORTS TO NFCR. X X X X false false false false false false false false false FRANKLIN C SALISBURY JR CHIEF EXECUTIVE OFFICER 311086 0 1099 53000 0 16271 0 381456 0 0 0 SUJUAN BA PRESIDENT/COO 310279 0 414 53000 0 13406 0 377099 0 0 0 YI WANG CHIEF STRATEGY OFFICER 191055 0 774 28712 0 2965 0 223506 0 0 0 KWOK LEUNG CFO/SECRETARY 133352 0 12000 774 23003 0 2400 0 171529 0 0 0 X 7 100090 stock market value X CHEMICALS AND EQUIPMENT 7 612015 FMV false true false PART III, LINE 4A - CANCER RESEARCH PROGRAM ACCOMPLISHMENTS: HIGHLIGHTS OF RESEARCH ACCOMPLISHMENTS ====================================== With support from our generous donors, NFCR-funded scientists have made numerous remarkable advances in the fight against cancer. Their research encompasses a wide variety of fields, many of which could ultimately lead to a cure for this deadly disease. Below are highlights of research accomplishments made by NFCR-funded scientists over the past year. Prevention ---------- Selenium Helps Prevent Cancer: Mitochondria are tiny cellular components that power up the cells and keep our body healthy and functional. However, mitochondria can also make cancer-causing damages to the cell when they themselves are damaged. Research has shown that selenium, a nutrient that can be found in certain nuts, fruits and nutrition supplements, may facilitate removing damaged mitochondria from the cell and thus help prevent cancer formation. NFCR-sponsored scientists are determining seleniums role and its molecular players in this vital cellular process. This research will further substantiate the beneficial effects of selenium for cancer prevention, and may also advance the development of cancer therapeutics that interact with mitochondria. Helmut Sies, M.D. Detection --------- Early Detection of the Silent Killer: Ovarian cancer often goes unnoticed until its too late to be treated effectively. Research led by NFCR-funded scientists is investigating new biomarkers and may shed a light on a better way to detect ovarian cancer early. These biomarkers are autoantibodies produced by a patients immune system against tumor proteins. The researchers will use more than 2,600 blood samples from clinical trials in the United States and England to analyze a panel of 6 autoantibodies. Promising preliminary results show that comparing to the existing markers, the new panel is able to detect many additional early ovarian cancers. Robert C. Bast, M.D. Powerful Blood Test for Cancer Detection and Treatment: A revolutionary blood test developed by NFCR-funded scientists can capture cancer cells that migrate away from primary tumors and circulate in a patients blood (called CTCs). The test has important clinical applications in multiple ways. For example, it can detect the return of cancer sooner than current procedures and monitor responsiveness of treatment in real-time to allow oncologists for timely treatment adjustments. Researchers are now using this powerful tool to identify the very reason that enables the lethal spread of the CTCs in a patients body. By determining the genes and molecular mechanisms that allow cells to migrate away, this research could lead to novel therapeutic strategies to suppress the fatal spread of cancer. Daniel Haber, M.D., Ph.D. Treatment --------- Combating Drug Resistance in Lung Cancer: Scientists supported by the Hillsberg Lung Cancer Translational Research Grant, a donor-initiated fund established with NFCR, have expanded their platform that identifies new drugs to combat drug resistance in lung cancer. One new research focus regards treatments for patients whose lung cancer has spread to the brain and has become resistant to targeted therapy. Scientists are using next generation sequencing (NGS) and other advanced molecular tests to identify the genetic abnormalities that may cause treatment resistance in the brain. These data will provide the preclinical rationale for developing new treatment strategies that effectively treat certain lung cancer patients whose tumor has spread to the brain. Alice Shaw, M.D., Ph.D. Innovative 2-in-1 Immunotherapy to Combat Kidney Cancer: Scientists at the NFCR Center for Antibody Engineering are developing an innovative combination immunotherapy that holds promise for treating metastatic kidney cancer more effectively. The treatment not only includes an antibody that inhibits an important protein that promotes tumor growth; it also unleashes the power of a patients immune system to launch more rigorous attacks than it normally would against cancer. This double immunotherapy packaged together into one agent has promising potential to become a new therapeutic for metastatic kidney cancer and other cancer types. Wayne A. Marasco, M.D., Ph.D. GBM AGILE - Accelerating Research for a Cure: Led by the best and brightest cancer researchers, GBM AGILE is a revolutionary global collaboration to test and develop new brain cancer treatments. Its personalized approach will allow us to accelerate the discovery of targeted treatments for individual patients. This global coalition has attracted over 150 participants from more than 40 leading cancer institutions across three continents. It implements a new generation of clinical trial called an adaptive trial which allows patients to be enrolled more quickly, receive treatment with multiple anti-cancer drugs simultaneously, and does not require years of follow-up to determine whether a new experimental treatment is beneficial. This revolutionary approach accelerates research for curing GBM, and will serve as a new clinical research model for combating other cancers as well. As a founding member of the coalition, NFCR has continued to take a leading role in this unprecedented effort. New Initiative in 2016 ---------------------- Thanks to the commitment of NFCR supporters, we were able to not only provide critical research funding for our existing programs, but to also launch entirely new initiative that will focus on triple negative breast cancer, the most deadly type of breast cancer. Triple Negative Breast Cancer Research Enabled by Charitable Bequest Gift: A significant bequest gift has enabled investigators Dr. Susan Band Horwitz, a molecular pharmacologist, and Dr. Amos Smith, a synthetic chemist, to pursue a cross-disciplinary approach to the design and synthesis of new hybrid drug compounds against triple negative breast cancer, the most deadly type of breast cancer. The new drugs will combine the power of two different agents and launch an effective attack toward the cancer cells with fewer side effects. This unique collaboration brings new hope to women whose cancer has stopped responding to the current treatment. Dr. Susan Band Horwitz and Dr. Amos Smith, III PART III, LINE 4B - CANCER PREVENTION EDUCATION TO THE PUBLIC: NFCR provides the public with free publications containing valuable information on the most up-to-date cancer preventive measures, treatment options, and diagnostic tools. Our powerful message sent to tens of millions of families and reaching tens of thousands of individuals through our social media channels (twitter and facebook)and through our blogs, helps to assure that fewer of today's healthy individuals will get cancer and more of today's cancer patients will become tomorrow's cancer survivors. Our public education materials include early cancer detection guide, a Childhood Cancer Chart, cancer prevention kits, recipes for healthy living, electronic and printed newsletters, the latest cancer headlines, and in-depth online cancer information. PART VI, SECTION A, LINE 2 - DIRECTORS/OFFICERS WITH FAMILY RELATIONSHIPS: FRANKLIN SALISBURY, CEO, AND SUJUAN BA, PRESIDENT/COO, ARE HUSBAND AND WIFE. PART VI, SECTION B, LINE 11B - REVIEW PROCESS OF FORM 990: THE NATIONAL FOUNDATION FOR CANCER RESEARCH'S PROCESS FOR REVIEWING THE FORM 990. ======================================================================= 1. FORM 990 WILL BE PREPARED AFTER ANNUAL AUDIT IS DONE. 2. THE FIRST DRAFT WILL BE REVIEWED BY THE CHIEF OPERATING OFFICER AND THE CHIEF FINANCIAL OFFICER. 3. AFTER RESOLVING ANY QUESTIONS OR UPDATES, THE REVISED DRAFT WILL BE SENT TO BOARD MEMBERS, PREFERABLY ELECTRONICALLY FOR THEIR REVIEW AND COMMENTS. 4. THE BOARD MEMBERS' COMMENTS, IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN. 5. THE RETURN WILL BE FILED WITH THE IRS PRIOR TO THE DESIGNATED DUE DATE OR EXTENDED DUE DATE. 6. THE STATE VERSION WILL BE PROVIDED TO STATES FOR REGISTRATION RENEWALS AND THE PUBIC PORTIONS OF THE RETURN WILL BE POSTED ON THE FOUNDATION'S WEBSITE. 7. IN THE OCCASION THAT THERE IS INSUFFICIENT TIME PRIOR TO FILING FORM 990 TO SHARE IT WITH THE BOARD, OR THERE IS ABSENCE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW OF FORM 990 BY THE BOARD PRIOR TO THE FILING DEADLINE, AN ELECTRONIC VERSION OF THE FILED RETURN WILL BE AVAILABLE FOR BOARD MEMBERS' REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO IRS. AN AMENDED RETURN, IF NECESSARY, WILL BE FILED. PART VI, SECTION B, LINE 12C - CONFLICT OF INTEREST POLICY COMPLIANCE: EACH DIRECTOR, PRIOR TO TAKING HIS/HER POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT IN WRITING TO THE CHAIRMAN OF THE BOARD A LIST OF ALL BUSINESSES OR OTHER ORGANIZATIONS OF WHICH HE/SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE FOUNDATION HAS, OR MIGHT REASONABLY IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST ANNUALLY. PART VI, SECTION B, LINE 15A/15B - OFFICERS COMPENSATION: ON AN ANNUAL BASIS, THE BOARD WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION. THIS PROCESS INCLUDES ALL OF THE FOLLOWING THREE ELEMENTS. ======================================================================== 1. REVIEW AND APPROVAL BY BOARD OF DIRECTORS: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, PROVIDED THAT PERSONS WITH CONFLICTS OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT AT ISSUE ARE NOT INVOLVED IN THIS REVIEW AND APPROVAL. EACH OFFICER'S PERFORMANCE IS EVALUATED BASED ON HIS OR HER JOB RESPONSIBILITIES, AND INTERNAL AND EXTERNAL GOALS SET IN THE PREVIOUS YEAR. 2. REVIEW OF "COMPARABLE COMPENSATION" DATA: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED USING DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPARABLE DATA ARE COMPILED BY THE FOUNDATION'S CHIEF FINANCIAL OFFICER AND/OR BY OUTSIDE COMPENSATION CONSULTANTS. COMPARABILITY DATA CAN INCLUDE COMPENSATION DATA FROM IRS FORM 990'S OF SIMILAR ORGANIZATIONS, PUBLISHED COMPENSATION SURVEYS, STUDIES AND GUIDES, AND OTHER SOURCES DEEMED APPROPRIATE AT THE TIME. 3. DOCUMENTATION AND RECORDKEEPING: THERE IS CONTEMPORANEOUS DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION ARRANGEMENT. THE RECORD IS KEPT BY THE SECRETARY OF THE FOUNDATION. PART VI, SECTION C, LINE 19-AVAILABILITY OF DOCUMENTS, POLICIES AND F/S: THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. THE FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE FOUNDTAION'S WEBSITE. PART IX, LINE 26 - JOINT COSTS ALLOCATION: NFCR is committed to efficiency and transparency. For more than 40 years, NFCR has been communicating with supporters, donors, and prospective donors by email, postal mail, phone and other means, both to request contributions and to educate the public, thereby upholding NFCRs mission statement (to support cancer research and public education relating to the prevention, early diagnosis, better treatments and ultimately, a cure for cancer). These free publications are sent to tens of millions of families and include materials such as early cancer detection guides, childhood cancer charts, cancer prevention kits and recipes for healthy living. As a result, in accordance with the Financial Accounting Standards Board (FASB) guidelines SOP 98-2 (ASC 958-720), we allocate a portion of our direct mail costs to program services and to fundraising. DARWIN FOUNDATION 4600 EAST-WEST HIGHWAY 525 BETHESDA MD 20814 371473821 CANCER RESEAR DC 501(C)3 509(A)(3) NFCR false RESEARCH FOR A CURE 4600 EAST-WEST HIGHWAY 525 BETHESDA MD 20814 010744146 CANCER RESEAR DC 501(C)3 509(A)(3) NFCR false false false false false false false false false false false false false false false true false false false false